Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MPO | P05164 | 2/20 | 0.39 |
| ▸ | GPR139 | Q6DWJ6 | 7/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31358989 | 1.00 | CNR2 (0.40) | CNR2FEN1MPOGPR139CNR1 | |
| SCHEMBL31359122 | 0.89 | CNR2 (0.38) | CNR2FEN1MPOGPR139CNR1 | |
| SCHEMBL31359033 | 0.89 | CNR2 (0.38) | CNR2FEN1MPOGPR139CNR1 | |
| SCHEMBL31359034 | 0.86 | GPR139 (0.42) | CNR2FEN1MPOGPR139CNR1 | |
| SCHEMBL31358971 | 0.86 | GPR139 (0.42) | CNR2FEN1MPOGPR139CNR1 | |
| SCHEMBL31359006 | 0.84 | GPR139 (0.35) | CNR2GPR139GRIN1GRIN2BJAK2 | |
| SCHEMBL31358997 | 0.84 | GPR139 (0.35) | CNR2GPR139GRIN1GRIN2BJAK2 | |
| SCHEMBL31359059 | 0.83 | GPR139 (0.37) | GPR139GRIN1GRIN2B | |
| SCHEMBL31358983 | 0.83 | FEN1 (0.40) | FEN1GPR139JAK2 | |
| SCHEMBL31359118 | 0.83 | FEN1 (0.40) | FEN1GPR139JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026726-A1 | QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, MYLK2 | CNR2 3943/4885FEN1 3928/4885MPO 4157/4885 |
| US-12559464-B2 | Quinazolinone dione compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CNR2 2026/4885FEN1 3297/4885MPO 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.